Baxter International Inc (BAX) · Oct 29, 2026 · Earnings
Beat — Adjusted EPS $0.58 vs ~$0.51–$0.52 consensus
Baxter’s Q3 earnings beat consensus on revenue and adjusted EPS, but underlying earnings declined and the stabilization story still has work ahead.
Baxter is still rebuilding after the Kidney Care divestiture, with management focused on cost reduction, operational stabilization and balance-sheet repair. That is the standing story: the company’s current full-year framework called for $1.95–$2.15 of adjusted EPS and $11.58–$11.69 billion of revenue, while analysts were expecting roughly $2.91 billion of Q3 revenue and $0.51–$0.52 of adjusted EPS.
The quarter cleared the bar, mainly through better-than-expected execution rather than a major change in the business trajectory. Revenue reached $2.976 billion, above the roughly $2.91 billion consensus, while adjusted diluted EPS was $0.58 versus approximately $0.51–$0.52 expected. Q3 sales increased 5% on both a reported and organic basis.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net sales (Financial Highlights) | $2,976M (+5%) | $2,835M | ~$2,910M |
| Adjusted diluted EPS (Adjusted EPS reconciliation) | $0.58 (-16%) | $0.69 | ~$0.51–$0.52 |
| Organic sales growth (Segment results) | 5% | — | — |
| Operating income (Income Statement) | $225M (+31%) | $172M | — |
| Free cash flow (Cash Flow statement) | $448M | — | — |
The operating foundation improved, but the earnings quality remains uneven. Medical Products & Therapies grew 6% organically, led by Infusion Therapies and Advanced Surgery, while Healthcare Systems & Technologies grew 4% organically. Yet adjusted EPS declined 16% year over year to $0.58, reflecting that revenue growth has not translated into higher underlying earnings. The reported profit increase was also helped by a $253 million gain on debt extinguishment and tax-related items, so GAAP net income materially overstates the quarter’s recurring improvement.
Cash generation is a meaningful positive for the restructuring story. Nine-month operating cash flow rose to $1.068 billion from $355 million, and free cash flow reached $705 million versus negative $18 million a year earlier. That gives Baxter more support for debt reduction and ongoing transformation, although the filing does not show enough balance-sheet detail to determine how much leverage has actually fallen.
The result is better than expected, but not a clean turnaround confirmation. Sales growth was broad—management said growth continued across all segments and divisions globally—and the company beat a lowered earnings bar. However, the core adjusted profit decline and continued special-item burden show that stabilization is progressing faster than durable earnings expansion. 〔0〕
Bottom line: Baxter delivered a narrow earnings beat and stronger cash flow, advancing the stabilization narrative. The bigger issue remains unresolved: underlying earnings are still shrinking despite mid-single-digit sales growth, so this is progress—not proof that the turnaround is finished.
Management’s October 29 outlook update
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!